Jan P. Nicolay, MD, PhD

At the 6th World Congress of Cutaneous Lymphoma, a group of world-leading CTCL expert consider what the field will abandon in the next decade.

Jan P. Nicolay, MD, PhD, explains how early single-cell data suggest mogamulizumab resistance switches on anti-apoptotic survival proteins.

Jan P. Nicolay, MD, PhD, explains why some patients stop responding to mogamulizumab comes down to the tumor shedding its target and new survival mechanisms the cell switches on.